Literature DB >> 24509642

Amyotrophic lateral sclerosis after embolization of cerebral arterioveneous malformations.

Anton Valavanis1, Urs Schwarz, Christian R Baumann, Michael Weller, Michael Linnebank.   

Abstract

Cerebral arterioveneous malformations (AVM) can cause neurological symptoms and carry a risk of hemorrhage. Therapeutic options to cure or reduce AVM include surgery, embolization, irradiation, and combinations thereof. Prompted by three index cases treated in our center, we studied whether AVM embolization is associated with an increased risk of subsequent amyotrophic lateral sclerosis (ALS). In a monocenter series, we retrospectively analyzed the new development of ALS in patients who had been treated with embolization of cerebral AVM from 1986 to 2010 (n = 1,114). After a median follow-up of 11 years (range, 0-25 years) after first embolization, seven patients developed ALS with a median latency of 14 years (range, 12-17 years) and a median age of ALS onset of 38 years (range, 28-52 years). In all cases, the initial limb of ALS symptom onset was ipsilateral to the AVM. Five patients died within the follow-up period, with a range of 1-4 years after the onset of ALS symptoms. The seven patients belonged to a subgroup of 34 patients who had in common a rare AVM architecture characterized by significant perinidal angiogenesis. All cases were partially treated by at least three embolization sessions. As there is no known association between AVM and ALS, AVM embolization must be taken into account to have contributed to the development of ALS in the seven patients with this rare AVM architecture. Searching for underlying mechanisms, we compared frozen serum samples that were available from four of the patients who developed ALS, from eight patients with AVM of other architecture, and less than three embolizations who did not develop ALS, and of 20 controls. The concentration of vascular endothelial growth factor (VEGF) in the serum was lowest in AVM patients who developed ALS (245 ± 154 pmol/l) and highest in controls (409 ± 178 pmol/l). Although this difference was not statistically significant in the small sample, it suggests that low VEGF production by AVM with significant angiogenesis, possibly due to multiple embolization procedures, might have contributed to ALS development. ALS should be considered as a late complication of multiple embolizations of cerebral AVM characterized by significant perinidal angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24509642     DOI: 10.1007/s00415-014-7260-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  26 in total

Review 1.  El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis.

Authors:  B R Brooks; R G Miller; M Swash; T L Munsat
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-12

Review 2.  The role of angiography in the evaluation of cerebral vascular malformations.

Authors:  A Valavanis
Journal:  Neuroimaging Clin N Am       Date:  1996-08       Impact factor: 2.264

3.  High erythropoietin and low vascular endothelial growth factor levels in cerebrospinal fluid from hypoxemic ALS patients suggest an abnormal response to hypoxia.

Authors:  N Just; C Moreau; P Lassalle; P Gosset; T Perez; V Brunaud-Danel; B Wallaert; A Destée; L Defebvre; A B Tonnel; D Devos
Journal:  Neuromuscul Disord       Date:  2006-12-04       Impact factor: 4.296

4.  Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

Authors:  B Oosthuyse; L Moons; E Storkebaum; H Beck; D Nuyens; K Brusselmans; J Van Dorpe; P Hellings; M Gorselink; S Heymans; G Theilmeier; M Dewerchin; V Laudenbach; P Vermylen; H Raat; T Acker; V Vleminckx; L Van Den Bosch; N Cashman; H Fujisawa; M R Drost; R Sciot; F Bruyninckx; D J Hicklin; C Ince; P Gressens; F Lupu; K H Plate; W Robberecht; J M Herbert; D Collen; P Carmeliet
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

5.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.

Authors:  Diether Lambrechts; Erik Storkebaum; Masafumi Morimoto; Jurgen Del-Favero; Frederik Desmet; Stefan L Marklund; Sabine Wyns; Vincent Thijs; Jörgen Andersson; Ingrid van Marion; Ammar Al-Chalabi; Stephanie Bornes; Rhiannon Musson; Valerie Hansen; Lars Beckman; Rolf Adolfsson; Hardev Singh Pall; Hervé Prats; Severine Vermeire; Paul Rutgeerts; Shigehiro Katayama; Takuya Awata; Nigel Leigh; Loïc Lang-Lazdunski; Mieke Dewerchin; Christopher Shaw; Lieve Moons; Robert Vlietinck; Karen E Morrison; Wim Robberecht; Christine Van Broeckhoven; Désiré Collen; Peter M Andersen; Peter Carmeliet
Journal:  Nat Genet       Date:  2003-08       Impact factor: 38.330

Review 6.  Prognostic factors in ALS: A critical review.

Authors:  Adriano Chiò; Giancarlo Logroscino; Orla Hardiman; Robert Swingler; Douglas Mitchell; Ettore Beghi; Bryan G Traynor
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

Review 7.  Role and therapeutic potential of VEGF in the nervous system.

Authors:  Carmen Ruiz de Almodovar; Diether Lambrechts; Massimiliano Mazzone; Peter Carmeliet
Journal:  Physiol Rev       Date:  2009-04       Impact factor: 37.312

8.  Simple risk predictions for arteriovenous malformation hemorrhage.

Authors:  D Kondziolka; M R McLaughlin; J R Kestle
Journal:  Neurosurgery       Date:  1995-11       Impact factor: 4.654

9.  Pathology of arteriovenous malformations embolized with isobutyl-2-cyanoacrylate (bucrylate). Report of two cases.

Authors:  H V Vinters; G Debrun; J C Kaufmann; C G Drake
Journal:  J Neurosurg       Date:  1981-11       Impact factor: 5.115

Review 10.  Inflammatory processes in amyotrophic lateral sclerosis.

Authors:  P L McGeer; E G McGeer
Journal:  Muscle Nerve       Date:  2002-10       Impact factor: 3.217

View more
  6 in total

1.  Embolization treatment of cerebral arteriovenous malformations and amyotrophic lateral sclerosis.

Authors:  Ourania Katsavarou; Stefanos Ntampos; Ioannis Sarmas; Nikos Triantafyllou; Sotirios Giannopoulos; Athanassios P Kyritsis
Journal:  Neurol Sci       Date:  2014-10-07       Impact factor: 3.307

2.  Prior medical conditions and the risk of amyotrophic lateral sclerosis.

Authors:  Meinie Seelen; Perry T C van Doormaal; Anne E Visser; Mark H B Huisman; Margot H J Roozekrans; Sonja W de Jong; Anneke J van der Kooi; Marianne de Visser; Nicol C Voermans; Jan H Veldink; Leonard H van den Berg
Journal:  J Neurol       Date:  2014-07-25       Impact factor: 4.849

Review 3.  Cell Death-Autophagy Loop and Glutamate-Glutamine Cycle in Amyotrophic Lateral Sclerosis.

Authors:  Shu Yuan; Zhong-Wei Zhang; Zi-Lin Li
Journal:  Front Mol Neurosci       Date:  2017-07-21       Impact factor: 5.639

Review 4.  Emerging links between cerebrovascular and neurodegenerative diseases-a special role for pericytes.

Authors:  Urban Lendahl; Per Nilsson; Christer Betsholtz
Journal:  EMBO Rep       Date:  2019-10-16       Impact factor: 8.807

Review 5.  Recent advances in amyotrophic lateral sclerosis.

Authors:  Nilo Riva; Federica Agosta; Christian Lunetta; Massimo Filippi; Angelo Quattrini
Journal:  J Neurol       Date:  2016-03-30       Impact factor: 4.849

6.  Cerebrovascular injury as a risk factor for amyotrophic lateral sclerosis.

Authors:  Martin R Turner; Raph Goldacre; Kevin Talbot; Michael J Goldacre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-08-10       Impact factor: 10.154

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.